Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 176

  • Quoted phrase not found.
1.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H.

JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

PMID:
28632866
2.

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.

Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.

3.

Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.

Antonucci I, Provenzano M, Sorino L, Balsamo M, Aceto GM, Battista P, Euhus D, Cianchetti E, Ballerini P, Natoli C, Palka G, Stuppia L.

J Hum Genet. 2017 Mar;62(3):379-387. doi: 10.1038/jhg.2016.138. Epub 2016 Dec 8.

PMID:
27928164
4.

BRCA1 and BRCA2 mutation testing in Cyprus; a population based study.

Loizidou MA, Hadjisavvas A, Pirpa P, Spanou E, Delikurt T, Tanteles GA, Daniel M, Kountourakis P, Malas S, Ioannidis G, Zouvani I, Kakouri E, Papamichael D, Marcou Y, Anastasiadou V, Kyriacou K.

Clin Genet. 2017 Apr;91(4):611-615. doi: 10.1111/cge.12886. Epub 2016 Nov 23.

PMID:
27882536
5.

Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.

Kraus C, Hoyer J, Vasileiou G, Wunderle M, Lux MP, Fasching PA, Krumbiegel M, Uebe S, Reuter M, Beckmann MW, Reis A.

Int J Cancer. 2017 Jan 1;140(1):95-102. doi: 10.1002/ijc.30428. Epub 2016 Sep 23.

PMID:
27616075
6.

Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.

Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, Christodoulou C, Fountzilas G, Yannoukakos D, Konstantopoulou I, Fostira F.

Clin Genet. 2017 Mar;91(3):482-487. doi: 10.1111/cge.12824. Epub 2016 Aug 22.

PMID:
27357818
7.

Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.

Byers H, Wallis Y, van Veen EM, Lalloo F, Reay K, Smith P, Wallace AJ, Bowers N, Newman WG, Evans DG.

Eur J Hum Genet. 2016 Nov;24(11):1591-1597. doi: 10.1038/ejhg.2016.57. Epub 2016 Jun 8.

PMID:
27273131
8.

BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.

Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S.

Genes Chromosomes Cancer. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.

PMID:
27225819
9.

Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases.

Anwar SL, Haryono SJ, Aryandono T, Datasena IG.

Asian Pac J Cancer Prev. 2016;17(4):1987-91.

10.

Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.

Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S.

Eur J Intern Med. 2016 Jul;32:65-71. doi: 10.1016/j.ejim.2016.03.010. Epub 2016 Apr 6.

PMID:
27062684
11.

Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.

Riahi A, Ghourabi ME, Fourati A, Chaabouni-Bouhamed H.

Breast Cancer. 2017 Mar;24(2):238-244. doi: 10.1007/s12282-016-0693-4. Epub 2016 Mar 30.

PMID:
27025497
12.

A new paradigm of genetic testing for hereditary breast/ovarian cancers.

Kwong A, Chen JW, Shin VY.

Hong Kong Med J. 2016 Apr;22(2):171-7. doi: 10.12809/hkmj154634. Epub 2016 Mar 14. Review.

13.

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE.

J Clin Oncol. 2016 May 1;34(13):1460-8. doi: 10.1200/JCO.2015.65.0747. Epub 2016 Mar 14.

14.

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.

Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, Kaplan Y, Dvir A, Barnes-Kedar I, Kadouri L, Semenisty V, Efrat N, Neiman V, Glasser Y, Michaelson-Cohen R, Katz L, Kaufman B, Golan T, Reish O, Hubert A, Safra T, Yaron Y, Friedman E.

Breast Cancer Res Treat. 2016 Jan;155(1):133-8. doi: 10.1007/s10549-015-3662-2. Epub 2015 Dec 19.

PMID:
26687385
15.

The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, Henrique R, Teixeira MR.

Fam Cancer. 2016 Jan;15(1):111-21. doi: 10.1007/s10689-015-9832-x.

PMID:
26289772
16.

Deleterious BRCA1/2 mutations in an urban population of Black women.

Lynce F, Smith KL, Stein J, DeMarco T, Wang Y, Wang H, Fries M, Peshkin BN, Isaacs C.

Breast Cancer Res Treat. 2015 Aug;153(1):201-9. doi: 10.1007/s10549-015-3527-8. Epub 2015 Aug 7.

PMID:
26250392
17.

Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.

Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ.

Ann Surg Oncol. 2015 Oct;22(10):3338-45. doi: 10.1245/s10434-015-4745-3. Epub 2015 Jul 28.

PMID:
26215194
18.

Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, -Hadjieva MS, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP.

BMC Cancer. 2015 Jul 17;15:523. doi: 10.1186/s12885-015-1516-2. Erratum in: BMC Cancer. 2017 Mar 16;17 (1):195.

19.

BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.

Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ.

PLoS One. 2015 Jun 5;10(6):e0127363. doi: 10.1371/journal.pone.0127363. eCollection 2015.

20.

Family history and outcome of young patients with breast cancer in the UK (POSH study).

Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM; POSH Study Steering Group.

Br J Surg. 2015 Jul;102(8):924-35. doi: 10.1002/bjs.9816. Epub 2015 May 20.

PMID:
25989914

Supplemental Content

Loading ...
Support Center